

ردیف	رشته پزشکی هسته ای	
۱۲	کتاب:	1. Nuclear Cardiology and Multimodal Cardiovascular Imaging: A Companion to Braunwald's Heart Disease. Marcelo Fernando Di Carli: 1st Edition; 2022 (<u>except for</u> these chapters: 1, 2, 4, 5, 12, 16, 28, 30, 31, 32). 2. Nuclear medicine and molecular imaging: The requisites; Janis O'malley, Harveyy Ziessman: 5th edition; 2021 (<u>except for</u> chapter 16) توجه: هدف از معرفی کتاب رکویزیت آموزش و آشنایی دستیاران با اصول اولیه تصویربرداری مرسوم در پزشکی هسته ای می باشد و در صورتیکه سوالات طرح شده در امتحان ارتقا، گواهینامه یا دانشنامه تداخلی با سایر منابع داشته باشد، ملاک پاسخدهی به سوالات کتاب رکویزیت نبوده و سایر منابع معرفی شده مبنای تصمیم گیری خواهد بود. 3. Fundamentals of Body CT; W. Richard Webb: 5th Edition, 2019 4. Nuclear Cardiac Imaging Principles and Application Ami E. Iskandrian and Fadi G. Hage: 6th edition; 2024 (only these chapters: 4, 6, 7, 11, 12) 5. Volterrani D, et al. Nuclear Medicine Textbook: Methodology and Clinical Applications, Springer; 2019 (except for these chapters: 17, 18, 20, 27, 36 ,40 ,41 ,42 ,43 ,44 ,45 ,46 ,51) 6. Ali Gholamrezanezhad et al. Radiology-Nuclear Medicine Diagnostic Imaging: A Correlative Approach, 2023 (only these chapters: 3, 5, 6, 9, 16, 19, 25, 30, 31)
	مجلات	Guidelines 1. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0 (2020) 2. The SNMMI and EANM procedural guidelines for diuresis renography in infants and children (2018) 3. SNMMI procedure standard/EANM practice guideline for diuretic renal scintigraphy in adults with suspected upper urinary tract obstruction 1.0 (2018) 4. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. European Journal of Nuclear Medicine and Molecular Imaging. 50, pages1466–1486 (2023) 5. Kevin J. Donohoe et al. Appropriate Use Criteria for Lymphoscintigraphy in Sentinel Node Mapping and Lymphedema/Lipedema. Society of Nuclear Medicine and Molecular Imaging. (2023). 6. Matthew D. Ringel, et al. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer, thyroid, Volume 35, Number 8, 2025 7. Francis GL, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015 Jul;25(7):716-59.

8. Ross DS, et al. American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. <i>Thyroid</i>. 2016 Oct;26(10):1343-1421 (2016). 9. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum. <i>Thyroid</i>. March 2017, 27(3): 315-389. 10. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i>., 50, pages 2830–2845 (2023). 11. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer (2018) 12. EANM guideline for ventilation/perfusion SPECT for diagnosis of pulmonary embolism and beyond (2019) 13. The SNMMI and EANM Practice Guideline for Small-Bowel and Colon Transit 1.0 (2013) 14. SNMMI procedure standard/EANM practice guideline for palliative nuclear medicine therapies of bone metastases (2023). 15. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. <i>Eur J Nucl Med Mol Imaging</i>. Apr; 49(5):1682-1699. (2022). 16. SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. <i>J Nucl Med</i> (2023) 17. The EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma (2019) 18. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F] FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i>. 49, pages, 2323–2341 (2022). 19. EANM guideline on the role of 2-[18F] FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA) (2021) 20. ASNC AND EANM cardiac amyloidosis practice points: ^{99m}Techetium- 3,3-diphosphono- 1,2-propanodicarboxylic acid (DPD) and ^{99m}Techetium hydroxymethylene diphosphonate (HMDP) imaging for transthyretin cardiac amyloidosis (2019) 21. National Osteoporosis Foundation (NOF) / International Society for Clinical Densitometry (ISCD) FRAX Implementation Guide (2019) 22. Hologic, Inc. Advanced Body Composition, Reporting and Interpretation: A Technical Discussion (2009) 23. The International Society for Clinical Densitometry (ISCD) official position for adults (2023) 24. The International Society for Clinical Densitometry (ISCD) official position for pediatrics (2019)		
--	--	--

25. Society of Nuclear Medicine Procedure Guideline for 99mTc-Exametazime (HMPAO)-Labeled Leukocyte Scintigraphy for Suspected Infection/Inflammation 3.0 (2004)
26. Lacrimal scintigraphy BNMS Guidelines (2018)
27. EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy (2019)
28. Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0 (2024)
29. The EANM guideline for radiosynoviorthesis (2021)
30. NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (2020)
31. SNMMI Procedure Standard/EANM Practice Guideline for Brain [18F]FDG PET Imaging, Version 2.0 (2024)

Articles in Journals

1. Mendichovszky I, Solar BT, Smeulders N, Easty M, Biassoni L. Nuclear medicine in pediatric nephro-urology: An Overview. Semin Nucl Med. 2017 May;47(3):204-228.
2. Martineau P, Bazarjani S, Zuckier LS. Artifacts and incidental findings encountered on dual-energy x-ray absorptiometry: Atlas and analysis. Semin Nucl Med. 2015;45(5):458-69.
3. Agrawal K, Esmail AA, Gnanasegaran G, Navalkissoor S, Mittal BR, Fogelman I. Pitfalls and limitations of radionuclide imaging in endocrinology. Semin Nucl Med. 2015 Sep;45(5):440-57.
4. Schreuder N, Koopman D, Jager PL, Kosterink JGW, van Puijenbroek E. Adverse Events of Diagnostic Radiopharmaceuticals: A Systematic Review. Semin Nucl Med. 2019 Sep;49(5):382-410.
5. Carrasquillo JA et al. Imaging of pheochromocytoma and paraganglioma. J Nucl Med 2021; 62:1033–1042.
6. Carrasquillo JA et al. Systemic radiopharmaceutical therapy of pheochromocytoma and paraganglioma. J Nucl Med 2021; 62:1192–1199.
7. <https://doi.org/10.2967/jnumed.121.262402>.
8. Volkan-Salanci B et al. Imaging in renal transplants: An update. Seminars in Nuclear Medicine. 2021;51(4):364-379.
9. Del Olmo-García MI et al. Prevention and management of hormonal crisis during theragnosis with Lu-DOTA-TATE in neuroendocrine tumors. A systematic review and approach proposal. J Clin Med. 2020 Jul 12;9(7):2203.

10. Mihailovic J et al. PET/CT Variants and Pitfalls in Head and Neck Cancers Including Thyroid Cancer. Seminars in Nuclear Medicine. 2021;51(5):419-440. 11. Lopci E et al. PET/CT Variants and Pitfalls in Lung Cancer and Mesothelioma. Seminars in Nuclear Medicine. 2021;51(5):458-473. 12. EG et al. PET/CT Variants and Pitfalls in Breast Cancers. Seminars in Nuclear Medicine. 2021;51(5):474-484. 13. Jayaprakasam VS et al. Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers. Seminars in Nuclear Medicine. 2021;51(5):485-501 14. Arslan E et al. PET/CT Variants and Pitfalls in Liver, Biliary Tract, Gallbladder and Pancreas. Seminars in Nuclear Medicine. 2021;51(5):502-518. 15. Imperiale A et al. Variants and Pitfalls of PET/CT in Neuroendocrine Tumors. Seminars in Nuclear Medicine. 2021;51(5):519-528. 16. Pilkington P et al. FDG-PET/CT Variants and Pitfalls in Haematological Malignancies. Seminars in Nuclear Medicine. 2021;51(6):554-571. 17. Agrawal A et al. PET/CT Normal Variants and Pitfalls in Pediatric Disorders. Seminars in Nuclear Medicine. 2021;51(6):572-583. 18. Benz MR et al. PET/CT Variants and Pitfalls in Bone and Soft Tissue Sarcoma. Seminars in Nuclear Medicine. 2021;51(6):584-592. 19. Dejanovic D et al. PET/CT Variants and Pitfalls in Gynecological Cancers. Seminars in Nuclear Medicine. 2021;51(6):593-610. 20. Vasireddi A et al. PET/CT Limitations and Pitfalls in Urogenital Cancers. Seminars in Nuclear Medicine. 2021;51(6):611-620. 21. Mei R et al. PET/CT Variants and Pitfalls in Prostate Cancer: What You Might See on PET and Should Never Forget. Seminars in Nuclear Medicine. 2021;51(6):621-632. 22. Pijl JP et al. Limitations and Pitfalls of FDG-PET/CT in Infection and Inflammation. Seminars in Nuclear Medicine. 2021;51(6):633-645. 23. UJ et al. Pitfalls on PET/CT Due to Artifacts and Instrumentation. Seminars in Nuclear Medicine. 2021;51(6):646-656. 24. Burkett BJ et al. How We Do It: A Multidisciplinary approach to 177 Lu DOTATATE peptide receptor radionuclide therapy. Radiology. 2021 Feb;298(2):261-274.		
--	--	--

25. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2); Robert Seifert. et al, European urology (2023) 26. Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with metastatic castration-resistant prostate cancer (mCRPC): clinical outcomes and safety. Lancet Oncol. 2023;24(5):451-64. 27. Johnson KA, Rabinovici GD, Sperling RA, Sadowsky CH, Fleisher AS, Pontecorvo MJ, et al. Updated appropriate use criteria for amyloid PET: Guidance from the Amyloid Imaging Taskforce, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med. 2025;66(2):205-15.		
--	--	--